tbuckley/cabot-search huggingface dataset:
Multi-laboratory validation study of multilocus variable-number tandem repeat analysis (MLVA) for Salmonella enterica serovar Enteritidis, 2015
Authors: Tansy Peters, Sophie Bertrand, Jonas T Björkman, Lin T Brandal, Derek J Brown, Tímea Erdõsi, Max Heck, Salha Ibrahem, Karin Johansson, Christian Kornschober, Saara M Kotila, Simon Le Hello, Taru Lienemann, Wesley Mattheus, Eva Møller Nielsen, Catherine Ragimbeau, Jillian Rumore, Ashley Sabol, Mia Torpdahl, Eija Trees, Alma Tuohy, Elizabeth de Pinna
Journal: Eurosurveillance (2017)

Multilocus variable-number tandem repeat analysis (MLVA) is a rapid and reproducible typing method that is an important tool for investigation, as well as detection, of national and multinational outbreaks of a range of food-borne pathogens. S almonella enterica serovar Enteritidis is the most common Salmonella serovar associated with human salmonellosis in the European Union/European Economic Area and North America. Fourteen laboratories from 13 countries in Europe and North America participated in a validation study for MLVA of S. Enteritidis targeting five loci. Following normalisation of fragment sizes using a set of reference strains, a blinded set of 24 strains with known allele sizes was analysed by each participant. The S. Enteritidis 5-loci MLVA protocol was shown to produce internationally comparable results as more than 90% of the participants reported less than 5% discrepant MLVA profiles. All 14 participating laboratories performed well, even those where experience with this typing method was limited. The raw fragment length data were consistent throughout, and the inter-laboratory validation helped to standardise the conversion of raw data to repeat numbers with at least two countries updating their internal procedures. However, differences in assigned MLVA profiles remain between well-established protocols and should be taken into account when exchanging data.
2017 ACC/AHA/HRS Guideline for the Evaluation and Management of Patients With Syncope: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society
Authors: Win-Kuang Shen, Robert S. Sheldon, David G. Benditt, Mitchell I. Cohen, Daniel E. Forman, Zachary D. Goldberger, Blair P. Grubb, Mohamed H. Hamdan, Andrew D. Krahn, Mark S. Link, Brian Olshansky, Satish R. Raj, Roopinder Kaur Sandhu, Dan Sorajja, Benjamin C. Sun, Clyde W. Yancy
Journal: Circulation (2017)
Early Reports of “Sycosis”
Authors: Niki Papavramidou, Anthony Karpouzis
Journal: JAMA Dermatology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
Overexpression of the Differentiation-Defective G-CSF Receptor Isoform IV Is Associated with a High Incidence of Relapses in Childhood Acute Myeloid Leukemia Treated with G-CSF
Authors: Stephanie Ehlers, Christin Herbst, Martin Zimmermann, Nicole Scharn, Manuela Germeshausen, Claudia Langebrake, Thomas Lehrnbecher, Jochen Harbott, Jan Stary, Michael Dworzak, Ursula Creutzig, Dirk Reinhardt
Journal: Blood (2008)
Abstract B14: The effect of sunitinib treatment in human melanoma xenografts: Associations with angiogenic profiles
Authors: Jon-Vidar Gaustad, Trude G. Simonsen, Lise Mari K. Andersen, Einar K. Rofstad
Journal: Cancer Research (2017)

Abstract The effect of antiangiogenic agents targeting the vascular endothelial growth factor A (VEGF-A) pathway has been reported to vary substantially in preclinical studies. Treatments with these agents have induced substantial reductions in vessel density in some tumor models, and minor or no reductions in vessel density in others. Additionally, the treatments have improved vascular function and oxygenation in some tumor models, and induced hypoxia in others. The purpose of this study was to investigate the effect of sunitinib treatment on the morphology and function of tumor vasculature in melanoma xenografts with different angiogenic profiles. A-07, U-25, D-12, and R-18 melanoma xenografts grown in dorsal window chambers were used as preclinical tumor models. Tumor-bearing mice were treated with sunitinib (40 mg/kg/day) or vehicle. Morphologic parameters of tumor vascular networks were assessed from high-resolution transillumination images, and tumor blood supply times were assessed from first-pass imaging movies recorded after a bolus of 155 kD tetramethylrhodamine isothiocyanate-labeled dextran was injected intravenously. Tumor hypoxia was assessed in immunohistochemical preparations by using pimonidazole as hypoxia marker, and the gene expression and the protein secretion rate of angiogenic factors were assessed by quantitative PCR and ELISA, respectively. The melanoma lines differed substantially in the expression of VEGF-A, VEGF-C, and platelet-derived growth factor A. Sunitinib treatment reduced vessel densities and induced hypoxia in all melanoma lines, and the magnitude of the effect was associated with the gene expression and protein secretion rate of VEGF-A. Sunitinib treatment also increased vessel segment lengths, reduced the number of small-diameter vessels, and inhibited growth-induced increases in the diameter of surviving vessels, but did not affect blood supply times. In conclusion, sunitinib treatment did not improve vascular function but reduced vessel density and induced hypoxia in human melanoma xenografts. The magnitude of the treatment-induced effect was associated with the angiogenic profiles of the melanoma lines. Citation Format: Jon-Vidar Gaustad, Trude G. Simonsen, Lise Mari K. Andersen, Einar K. Rofstad. The effect of sunitinib treatment in human melanoma xenografts: Associations with angiogenic profiles. [abstract]. In: Proceedings of the AACR Special Conference on Engineering and Physical Sciences in Oncology; 2016 Jun 25-28; Boston, MA. Philadelphia (PA): AACR; Cancer Res 2017;77(2 Suppl):Abstract nr B14.
Multi-institutional prospective study to explore the efficacy of oral nutritional supplements for the patients undergoing gastrectomy against gastric cancer (CCOG1301).
Authors: Nobutake Tanaka, Daisuke Kobayashi, Kiyoshi Ishigure, Yoshinari Mochizuki, Hiroshi Nakayama, Yuki Morioka, Kazunari Misawa, Tomomi Okada, Akira Fujioka, Masaya Yamanaka, Yasuaki Uno, Hirotaka Hasegawa, Tatsuki Matsumura, Yoshiyasu Kato, Yasuyuki Asai, Chie Tanaka, Seiji Ito, Michitaka Fujiwara, Hiroshi Kojima, Yasuhiro Kodera
Journal: Journal of Clinical Oncology (2015)

e15039 Background: Gastrectomy with lymphadenectomy and adjuvant chemotherapy is one of standards for treatment of gastric cancer (GC). Postoperative malnutrition is deemed inevitable, however, and there is paucity of evidence for effective nutritional intervention. A prospective trial was conducted to evaluate the efficacy of postoperative oral nutritional supplements (ONS). Methods: Stage I~III GC patients with BMI less than 25 who undergo distal or total gastrectomy received oral administration of Racol NF (Otsuka Pharmaceutical Factory, Japan), a liquid enteral nutritional formula, as a supplement to regular meals. Racol at a recommended dose of 400 kcal/400 ml per a day was started within 7 days postoperatively and was continued for 3 postoperative months. Data on treatment compliance were collected through a questionnaire filled-in by the patients. Primary end point was ratio of the body weight loss (BWL) at 3 months postoperatively. Secondary end points were the compliance of Racol and changes in body composition and serum biochemistry at 3 months postoperatively. Results: 118 patients were registered before surgery, 80 of whom were eligible for efficacy analyses. 38 ineligible patients consisted of 15 whose compliance records could not be retrieved, 11 who were found to have Stage IV disease and 8 who failed to start Racol within 7 postoperative days. The mean daily intake of Racol was 201 ml. There was significant correlation between Racol compliance and BWL ratio (p < 0.01). Lower BWL ratio was observed among 39 high-compliance patients (H group) who could take > 200 ml per day of Racol when compared with 41 low-compliance patients (L group) (6.3% vs 10.5%, p < 0.01), although there were no differences in the background clinicopathological features. The actual decreases in body weight were from 55.6 to 52.0kg for H group and from 57.2 to 51.4 kg for L group (p = 0.02). There were no differences regarding serum biochemistry findings. Conclusions: ONS Racol led to a significant reduction in BWL at more than half of the recommended dose. Whether that reduction leads to higher compliance for adjuvant chemotherapy calls for further assessment. Clinical trial information: UMIN000011410.
Phase I Results of Perifosine (KRX-0401) in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma (MM)
Authors: Andrzej Jakubowiak, Paul Richardson, Todd M. Zimmerman, Melissa Alsina, Jonathan L. Kaufman, Colleen Harvey, Christine Brozo, Tara Kendall, Amanda McAllister, Teru Hideshima, Peter Sportelli, Lesa Gardner, Kenneth C. Anderson, Kathy Giusti
Journal: Blood (2008)
Acupuncture for Migraine Prevention
Authors: Amy A. Gelfand
Journal: JAMA Internal Medicine (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Opening pressures and atelectrauma in acute respiratory distress syndrome
Authors: Massimo Cressoni, Davide Chiumello, Ilaria Algieri, Matteo Brioni, Chiara Chiurazzi, Andrea Colombo, Angelo Colombo, Francesco Crimella, Mariateresa Guanziroli, Ivan Tomic, Tommaso Tonetti, Giordano Luca Vergani, Eleonora Carlesso, Vladimir Gasparovic, Luciano Gattinoni
Journal: Intensive Care Medicine (2017)
Novel Myelodysplastic Syndromes-like Mouse Models By Cooperating Genetic/Epigenetic Mutations Reveal the Critical Role of HIF-1α for Disease Development
Authors: Yoshihiro Hayashi, Yue Zhang, Xiaomei Yan, Goro Sashida, Zefeng Xu, Yunzhu Dong, Hironori Harada, Zhijian Xiao, Gang Huang
Journal: Blood (2014)
Pilot Study of Radiation-Targeted Donor Lymphocyte Infusion for Cancer Progression after Allogeneic Hematopoietic Stem Cell Transplantation
Authors: Nancy M. Hardy, Deborah Citrin, Frances T. Hakim, Daniele N. Avila, Bazetta Blacklock-Schuver, Stephanie Cotton, Monica Cho, Daniel H. Fowler, Juan C. Gea-Banacloche, Noa G. Holtzman, Karen A. Kurdziel, Sarfraz Memon, Steven Z. Pavletic, Stefania Pittaluga, Jeremy J. Rose, Claude Sportes, Jennifer S. Wilder, Ronald E. Gress, Michael R. Bishop
Journal: Blood (2015)
PEG-Intron Therapy in Patients with Philadelphia Chromosome-Negative Myeloproliferative Disorders (MPD): Final Result of a Phase II Study.
Authors: Elias Jabbour, Hagop Kantarjian, Charles A. Koller, Stefan Faderl, Alessandra Ferrajoli, Mary Ann Richie, Guillermo Garcia-Manero, Jorge Cortes, Zeev Estrov, Farhad Ravandi-Kashani, Francis Giles, Srdan Verstovsek
Journal: Blood (2006)
Update of a GITIL Cohort Study: Frontline High Dose Sequential Chemotherapy with Rituximab and Autologous Stem Cell Transplantation Induces a High Rate of Long-Term Remissions in Patients with Mantle Cell Lymphoma
Authors: Sergio Cortelazzo, Michele Magni, Corrado Tarella, Michael Mian, Atto Billio, Andrea Rossi, Maddalena Marchesi, Andrea Gallamini, Paolo Corradini, Fabio Ciceri, Guido Parvis, Ignazio Majolino, Caterina Patti, Salvo Mirto, Fabio Benedetti, Giovanni Pizzolo, Alessandro M. Gianni, Alessandro Rambaldi
Journal: Blood (2007)
Appropriate Management of Patients With Peripheral Arterial Disease
Authors: Robert B. Patterson
Journal: JAMA Surgery (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
An Open, Phase I Study of Cediranib in Patients with Acute Myeloid Leukemia (AML).
Authors: Walter Fiedler, Rolf Mesters, Michael Heuser, Gerhard Ehninger, Oliver G. Ottman, Wolfgang E. Berdel, Ute Zirrgiebel, Jane Robertson, Thomas A. Puchalski, Sandra R. Brave, Juliane M. Jürgensmeier, Hubert Serve
Journal: Blood (2007)
The VITAL Amyloidosis Study: A Randomized, Double-Blind, Placebo-Controlled, Global, Phase 3 Study of NEOD001 in Patients with AL Amyloidosis and Cardiac Dysfunction
Authors: Michaela Liedtke, Giampaolo Merlini, Heather Landau, Raymond L. Comenzo, Vaishali Sanchorawala, Brendan M. Weiss, Jeffrey A. Zonder, Jackie Walling, Gene G. Kinney, Martin Koller, Morie A. Gertz
Journal: Blood (2016)
In Acute Myeloid Leukemia, the Use in Induction of Standard Dose Arac Is Associated with a Better Quality of Response as Compared to An Induction Regimen Containing High Dose Arac.
Authors: Luca Maurillo, Francesco Buccisano, Alessandra Spagnoli, Maria Ilaria Del Principe, Benedetta Neri, Chiara Sarlo, Giovanni Del Poeta, Francesco Lo Coco, Sergio Amadori, Adriano Venditti
Journal: Blood (2009)
PP58. CLINICAL AND RADIOLOGICAL FEATURES OF LEPTOMENINGEAL METASTASES
Authors: Dr Ester Pfeifer, Dr Jeremy Rees
Journal: Neuro-Oncology (2017)

INTRODUCTION: Leptomeningeal metastases (LM) is an uncommon complication of cancer and is associated with a variety of different clinical presentations. AIM: The aim of this study was to assess clinical, radiological, and survival data in all cases of LM identified by cytological examination of cerebrospinal fluid (CSF) at the University College London Hospital Foundation Trust between 2010 and 2016. METHODS: CSF cytology reports from 2010–2016 were analysed and patients with malignant cells in CSF were identified. Those with positive CSF cytology as part of staging investigations for primary central nervous system (CNS) tumours and high grade lymphomas were excluded. Clinical, biochemical and magnetic resonance imaging (MRI) data were obtained for the confirmed cases from the Electronic Patient Record. RESULTS: Twenty patients (M:F 15:5) out of 4424 patients (0.5%) were identified as positive for malignant cells. All had been previously diagnosed with cancer of the breast (n=11), lung (n=7), bladder, oesophagus and neuroendocrine tumour (1 each). Two of the patients with breast cancer had a second primary tumour (melanoma and meningioma) and two patients with lung cancer also had a history of breast cancer. Median survival after diagnosis was 32 days (range 5–273 days, n=16). Only two patients, both with breast cancer, survived more than three months; both had normal imaging at diagnosis. The patient with longest survival had CSF taken as part of a dementia workup and found to have malignant cells. 3 patients died within 2 weeks of diagnosis. Clinical presentations were cognitive decline (n=8), of whom 5 presented with additional symptoms including headache, gait disturbance and limb weakness, hydrocephalus (n=6), radiculopathy (n=3), severe headache (n=2), or headache with cranial nerve palsies (n=1). Contrast-enhanced MRI of the brain showed nodular or linear meningeal enhancement (n=9, of whom 3 also had cerebral metastases), cerebral metastases alone (n=5), subtle meningeal enhancement (n=3) and normal appearances (n=3). Following diagnosis, the 6 patients with hydrocephalus had ventriculoperitoneal shunt insertion and 3 had Ommaya reservoir for intrathecal chemotherapy. CONCLUSIONS: In this small series, LM presented in a variety of ways and only occurred in patients with known cancer. All but two patients died within two months. MRI was highly suggestive of LM in less than half the patients.
Reduced-Intensity Allogeneic Peripheral Blood Stem Cell Transplantation for High-Risk Acute Lymphoblastic Leukemia: A Potential Therapeutic Approach for High Risk ALL Patients Not Eligible for Full Intensity Transplantation
Authors: A. Stein, J Palmer, M O’Donnell, N. Kogut, R Spielberger, ML Slovak, NC Tsai, S. J Forman
Journal: Blood (2008)
Antiangiogenic agents (AAs) in metastatic oesophago-gastric cancer (mOGC): A systematic review and meta-analysis.
Authors: David Chan, David Goldstein, Katrin Marie Sjoquist, Nick Pavlakis
Journal: Journal of Clinical Oncology (2015)

e15111 Background: Studies of AAs, combined with chemotherapy (chemo) or as monotherapy in mOGC, have reported mixed outcomes. We undertook a systematic review and meta-analysis to determine their overall benefits and harms. Methods: Randomized controlled trials in mOGC were sought investigating the addition of AA (monoclonal antibodies and tyrosine kinase inhibitors) to standard therapy (best supportive care or chemo). The primary endpoint was overall survival (OS) with secondary endpoints progression-free survival (PFS), overall response rate (ORR) and toxicity. Meta-analysis was performed according to CONSORT guidelines and standard methods with hazard ratios (HR) and odds ratios (OR). Subgroup analyses were performed by region, age, performance status, histological type and number of metastatic sites. Results: 13 trials evaluating 3229 patients were included in the efficacy analysis. The addition of AAs was associated with improved OS: HR 0.80 (95% CI 0.74-0.87, p < 0.00001) and improved PFS: HR 0.67 (95% CI 0.62-0.72, p < 0.00001). OS was not improved in the 1st-line setting: HR 0.91 (95% CI 0.80-1.05) but was improved in 2nd/3rd line settings: HR 0.74 (95% CI 0.66-0.82). OS benefit was observed in all regions – Europe (HR 0.80, 95% CI 0.69-0.93), Asia (HR 0.82, 95% CI 0.73-0.93) and Pan-America (HR 0.60, 95% CI 0.45-0.81) without significant subgroup interaction. 7 trials evaluating 2512 patients were pooled for any toxicity > = Grade 3. Pooled toxicity OR was 1.40 (95% CI 1.17-1.66). Conclusions: The addition of AAs to standard therapy in mOGC improves OS in 2nd/3rd line settings but not in the 1st-line setting. OS benefit was observed in each of the 3 major geographical regions. This benefit is at the expense of increased overall toxicity.
RNAi Screening Identifies A Novel Role for A-Kinase Anchoring Protein 12 (AKAP12) in B Cell Development and Function
Authors: Mutlu Kartal-Kaess, Luisa Cimmino, Simona Infantino, Mehmet Yabas, Jian-Guo Zhang, Laura Tuohey, Irwin H. Gelman, John D. Scott, Stephen L. Nutt, Anselm Enders, David Tarlinton, Ross A Dickins
Journal: Blood (2012)
The mTOR Inhibitor Everolimus Overcomes CXCR4-Mediated Resistance to HDAC Inhibitor Panobinostat through Inhibition of p21 and Mitosis Regulators, Sensitizing MM Cells to DNA-Damaged Induced Apoptosis
Authors: Katia Beider, Valeria Voevoda, Hanna Bitner, Evgenia Rosenberg, Hila Magen, Olga Ostrovsky, Merav Leiba, Noya Shilo, Avichai Shimoni, Michael Milyavsky, Amnon Peled, Arnon Nagler
Journal: Blood (2016)
Rapid and Efficient Mobilization of Murine Hematopoietic Stem and Progenitor Cells with Nox-A12, a New Spiegelmers®-Based CXCR4/SDF-1(CXCL12) Antagonist
Authors: Marina Scheller, Frank Schwoebel, Doerte Vossmeyer, Achim Leutz
Journal: Blood (2011)
Rehabilitation for people living with dementia: A practical framework of positive support
Authors: Linda Clare
Journal: PLoS Medicine (2017)

Awareness of the need to improve accessibility of services and opportunities for people with disabilities is growing, but people with "hidden" disabilities such as dementia can be excluded from these developments.Conceptualizing dementia in terms of social disability highlights the way in which symptoms such as memory problems-and the secondary effects of these, such as loss of confidence or negative reactions from others-affect the possibility of engaging in activities and participating in society [1].It also suggests some practical solutions that can support participation and inclusion and promote the ability to live well [2].Activity limitation and participation restriction can be tackled from two directions.From a community perspective, the focus is on dismantling external barriers to participation by changing public attitudes and creating accessible, dementia-friendly environments.A growing social movement led by people with dementia, Alzheimer associations, and supporters promotes acceptance, inclusion, and awareness of rights [3].From a personal perspective, the focus is on enabling people with dementia to participate in everyday life, and in their families and communities, in a way that is meaningful to them.This is the aim of rehabilitation [4].
Abstract P2-06-01: Non-genetic risk factors improve accuracy of breast cancer risk assessment for women at high familial risk: Comparison of risk estimation models using the prospective family study cohort (ProF-SC)
Authors: MB Terry, K-A Phillips, Y Liao, RJ MacInnis, GS Dite, MB Daly, EM John, IL Andrulis, SS Buys, R Buchsbaum, JL Hopper
Journal: Cancer Research (2017)

Abstract This abstract was withdrawn by the authors.
Clinical benefits of treatment with SQ house dust mite sublingual tablet in house dust mite allergic rhinitis
Authors: P. Demoly, J. Kleine‐Tebbe, D. Rehm
Journal: Allergy (2017)

Treatment with SQ (standardised quality) house dust mite sublingual tablet for 1 year resulted in a decreased probability of having an allergic rhinitis (AR) exacerbation day (from 11% [placebo] to 5% [SQ house dust mite sublingual tablet]) and an increased probability of having a mild AR day (from 16% [placebo] to 34% [SQ house dust mite sublingual tablet]).